IP Library › Patent Application 14255961
Patent Application
App. No. 14/255,961

SYSTEMS AND METHODS FOR DELIVERING CROSS-LINKED HALYURONIC ACID INTO A PATIENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/255,961
Abstract

Systems and methods are disclosed for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer; injecting the mixture into a patient and during or after injection, cross-linking the polymer in the patient; and augmenting soft tissue with the biocompatible cross-linked polymer.

Claims (33)

1 . A method for cosmetic augmentation, comprising:

storing a non-toxic biocompatible cross-linker;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer, wherein the polymer reacts in-situ to alter physical properties of the polymer from a deformable state to a non-deformable state;

mixing the biocompatible cross-linker and polymer into a mixture;

injecting the mixture into a patient and during or after injection, cross-linking the polymer in the patient; and

augmenting soft tissue with the biocompatible cross-linked polymer.

2 . The method of claim 1 , comprising introducing the polymer into the shell of a soft tissue human implant prior to or during implantation of the shell with a lumen in a human body.

3 . The method of claim 1 , comprising cross-linking the polymer, wherein a cross linking reaction occurs outside the shell or in-situ inside the shell.

4 . The method of claim 1 , wherein the polymer comprises one of collagens, PEG, hyaluronic acids, celluloses, proteins, saccharides, biodegradable and bioresorbable biocompatible materials.

5 . The method of claim 1 , wherein the polymer comprises an extracellular matrix of a biological system.

6 . The method of claim 1 , comprising using cross linkers and forming homo-polymers or to form copolymers by crosslinking with other polymer species.

7 . The method of claim 1 , comprising adding a substance to the composition for biocompatibility.

8 . The method of claim 1 , comprising controlling drug releases at predetermined timing in anticipation of an onset of a negative physiological event in response to an invading foreign bodies.

9 . The method of claim 1 , comprising fast releasing, medium or slow releasing the composition.

10 . The method of claim 1 , comprising adding anesthetics, lidocaine or compound to reduce or eliminate acute inflammatory reactions to the pharmaceutical substance.

11 . The method of claim 1 , comprising adding one or more compositions selected from the group consisting of steroids, corticosteroids, dexamethasone, triamcinolone.

12 . The method of claim 1 , comprising providing an antiproliferative compound.

13 . The method of claim 1 , wherein the substance comprises paclitaxel, serolimas.

14 . The method of claim 1 , comprising controlling the scar formation process around a foreign body including capsular formation.

15 . The method of claim 1 , comprising optimizing degradation profile of the composition.

16 . The method of claim 1 , comprising minimizing migration of the composition.

17 . The method of claim 1 , comprising controlling the number average molecular weight (Mn) and the polydispersity index. The method of claim 1 , comprising characterizing a target tissue, and maintaining a consistency of the composition in particle size and population densities.

18 . The method of claim 1 , comprising co-cross-linking glycosaminoglycan chemically with at least one other polymer including hyaluronan or hylan.

19 . The method of claim 1 , wherein the chemically cross-linked glycosaminoglycan is hyaluronan or hylan.

20 . The method of claim 1 , comprising in-situ non-covalent bonding including one of: hydrogen associatation, charge or ionic interactions, pH, osmolality.

21 . The method of claim 1 , comprising modeling a 3D model of a human body and continuously updating a current shape of breast or butt from the 3D model to fit to a desired shape.

22 . The method of claim 1 , comprising injecting with a mechanical pump the biocompatible crosslinked polymer under soft tissue in a minimally invasive manner.

23 . A method for cosmetic augmentation, comprising:

storing a non-toxic biocompatible cross-linker;

storing a biocompatible polymer having a multi-phase mixture with a predetermined controlled release of selected pharmaceutical substance to modulate soft tissue response to the polymer;

mixing the biocompatible cross-linker and polymer into a mixture;

injecting the mixture into a patient and during or after injection, cross-linking the polymer in the patient; and

augmenting soft tissue with the biocompatible cross-linked polymer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2015
From: PHAN, LOC X; NGUYEN, PHI; TRAN, BAO
To: MIBA MEDICAL INC.
Reel/Frame 035826/0106 →